Immune Design Corp (IMDZ)

NASDAQ
Currency in USD
Disclaimer
5.85
0.00(0.00%)
Closed
Day's Range
5.845.85
52 wk Range
0.005.85
Prev. Close
5.85
Open
5.84
Day's Range
5.84-5.85
52 wk Range
0-0
Volume
0
Average Vol. (3m)
607,193
1-Year Change
0%
Shares Outstanding
48,365,248
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More

Immune Design Corp Company Profile

Immune Design Corp., a clinical-stage immunotherapy company, focuses on cancer with in vivo approaches to enable the body’s immune system to fight disease. The company develops products based on its ZVex and GLAAS discovery platforms. Its lead product candidate is G100, a monotherapy and combination therapy that is in Phase II clinical trials for treating patients with follicular non-Hodgkin lymphoma. The company has collaboration and license agreements with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington. As of April 2, 2019, Immune Design Corp. operates as a subsidiary of Merck Sharp & Dohme Corp. As of April 2, 2019, Immune Design Corp. operates as a subsidiary of Merck & Co., Inc.

Income Statement